<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623426</url>
  </required_header>
  <id_info>
    <org_study_id>119247</org_study_id>
    <secondary_id>U10EY024527</secondary_id>
    <secondary_id>ML29257</secondary_id>
    <nct_id>NCT02623426</nct_id>
  </id_info>
  <brief_title>Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial</brief_title>
  <acronym>MERIT</acronym>
  <official_title>Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will&#xD;
      compare the relative efficacy and safety of intravitreal methotrexate, intravitreal&#xD;
      ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular&#xD;
      edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a&#xD;
      parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6&#xD;
      month clinic visit. The primary outcome is percent change in central subfield thickness from&#xD;
      the baseline OCT measurement to the 12 week visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Macular edema (ME) is the most common structural complication and cause of visual impairment&#xD;
      and legal blindness in uveitis patients. Traditional approaches to the treatment of uveitic&#xD;
      ME have included the use of regional corticosteroid therapy, delivered periocularly,&#xD;
      including posterior sub-Tenon's and orbital floor injections, or via the intravitreal route.&#xD;
      While corticosteroid injections may reduce ME and improve vision, the effect is often&#xD;
      variable with a limited duration. Persistent macular edema is a common occurrence and often&#xD;
      requires repeated intravitreal injections of corticosteroids, which expose eyes to a&#xD;
      significant risk of increased intraocular pressure ocular and cataract development. The often&#xD;
      refractory nature of uveitic ME and its impact on visual function underscores the need to&#xD;
      identify effective alternative medical therapeutic options. Recent pilot studies have shown&#xD;
      intravitreal methotrexate (MTX) and intravitreal ranibizumab (Lucentis®, Genentech Inc., San&#xD;
      Francisco, CA) to be promising treatments for uveitic ME, and intravitreal dexamethasone&#xD;
      implant (Ozurdex®, Allergan, Irvine, CA) has recently been approved by the U.S. FDA for&#xD;
      uveitic ME in patients with non-infectious uveitis. In addition to being effective,&#xD;
      intravitreal MTX and ranibizumab potentially may have less ocular side effects than&#xD;
      corticosteroids, particularly less IOP elevation. However, the relative efficacy of these&#xD;
      treatments is unknown. The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory&#xD;
      Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal&#xD;
      methotrexate, ranibizumab, and dexamethasone implant. MERIT is a parallel design (1:1:1),&#xD;
      randomized comparative effectiveness trial with an anniversary close-out at the 6 month&#xD;
      clinic visit. The primary outcome is percent change in central subfield thickness from the&#xD;
      baseline OCT measurement to the 12 week visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in central subfield thickness from the baseline OCT measurement</measure>
    <time_frame>At 12-week visit</time_frame>
    <description>The primary outcome is the percent change in central subfield thickness from the baseline OCT measurement at the 12-week visit. The assessment of OCT outcomes will be performed by masked readers. The 12-week visit was chosen as the time to assess the primary outcome because the ranibizumab treatment arm specifies injections at baseline, 4 weeks and 8 weeks in all participants, and because the peak benefit for the dexamethasone pellet appears to be at the 8 to 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP Elevation of &gt;=24 mm Hg</measure>
    <time_frame>During 24 weeks of follow-up</time_frame>
    <description>Rate of IOP elevation of &gt;=24 mm Hg during follow-u</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP Elevation of &gt;=30 mm Hg</measure>
    <time_frame>During 24 weeks of follow-up</time_frame>
    <description>Rate of IOP elevation of &gt;=30 mm Hg during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP Elevation of &gt;=10 mm Hg From Baseline</measure>
    <time_frame>During 24 weeks of follow-up</time_frame>
    <description>Rate of IOP elevation of &gt;=10 mm Hg from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Macular Thickness as Measured by OCT</measure>
    <time_frame>Over 24 weeks of follow-up</time_frame>
    <description>Percent change in macular thickness as measured by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&gt;= 20% Reduction in Macular Thickness (or Normalization Even if &lt;20% Reduction</measure>
    <time_frame>Over 24 weeks of follow-up</time_frame>
    <description>Proportion of eyes with &gt;=20% reduction in macular thickness (or normalization of macular thickness even if there is &lt;20% reduction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of macular edema</measure>
    <time_frame>Over 24 weeks of follow-up</time_frame>
    <description>Proportion of eyes with resolution of macular edema defined as normalization of the macular thickness, i.e., &lt;260 um on the standard scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best-corrected Visual Acuity</measure>
    <time_frame>Over 24 weeks of follow-up</time_frame>
    <description>Mean change in best-corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitreous Hemorrhage</measure>
    <time_frame>During 24 weeks of follow-up</time_frame>
    <description>Count of vitreous hemorrhage as an immediate complication of injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Tear/Detachment</measure>
    <time_frame>During 24 weeks of follow-up</time_frame>
    <description>Count of retinal tears/detachments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endophthalmitis</measure>
    <time_frame>During 24 weeks of follow-up</time_frame>
    <description>Occurrence of endophthalmitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe vision loss</measure>
    <time_frame>During 24 weeks of follow-up</time_frame>
    <description>Severe vision loss (&gt;= 15 standard letters)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Uveitis</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Dexamethasone intravitreal implant 0.7mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible eye(s) treated at study visit M01 (week 0).&#xD;
Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.&#xD;
Retreatment permitted at later time points if retreatment criteria met.&#xD;
Re-treatment criteria:&#xD;
Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.&#xD;
IOP of &lt;25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)&#xD;
Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal methotrexate 400µg in 0.1mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible eye(s) treated at study visit M01 (week 0).&#xD;
Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.&#xD;
Retreatment permitted at later time points if retreatment criteria met.&#xD;
Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal ranibizumab 0.5mg in 0.05mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).&#xD;
Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.&#xD;
Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.&#xD;
Re-treatment permitted at later time points if re-treatment criteria met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant 0.7 mg</intervention_name>
    <description>Standard preparation as described for intravitreal injections.</description>
    <arm_group_label>Dexamethasone intravitreal implant 0.7mg</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Methotrexate 400 µg</intervention_name>
    <description>Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.</description>
    <arm_group_label>Intravitreal methotrexate 400µg in 0.1mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Ranibizumab 0.5 mg</intervention_name>
    <description>Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.</description>
    <arm_group_label>Intravitreal ranibizumab 0.5mg in 0.05mL</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patient level inclusion criterion&#xD;
&#xD;
          1. 18 years of age or older;&#xD;
&#xD;
             Eye level inclusion criteria - at least one eye must meet all of the following&#xD;
             conditions&#xD;
&#xD;
          2. Inactive or minimally active non-infectious anterior, intermediate, posterior or&#xD;
             panuveitis, as defined by SUN132 criteria as ≤ 0.5+ anterior chamber cells, ≤ 0.5+&#xD;
             vitreous haze grade and no active retinal/choroidal lesions for a minimum of 4 weeks;&#xD;
&#xD;
          3. Macular edema (ME) defined as the presence of macular thickness greater than the&#xD;
             normal range for the OCT machine being used (see cut points below), regardless of the&#xD;
             presence of cysts, following an intravitreal corticosteroid injection (≥ 4 weeks&#xD;
             following intravitreal triamcinolone injection or ≥ 12 weeks following intravitreal&#xD;
             dexamethasone implant injection);&#xD;
&#xD;
             Greater than 300 μm for Zeiss Cirrus Greater than 320 μm for Heidelberg Spectralis&#xD;
             Greater than 300 μm for Topcon 3DOCT&#xD;
&#xD;
          4. Baseline fluorescein angiogram that, as assessed by the study ophthalmologist, is&#xD;
             gradable for degree of leakage in the central subfield;&#xD;
&#xD;
          5. Best corrected visual acuity (BCVA) 5/200 or better;&#xD;
&#xD;
          6. Baseline intraocular pressure &gt; 5 mm Hg and ≤ 21 mm Hg (current use of ≤3 intraocular&#xD;
             pressure-lowering medications and/or prior glaucoma surgery are acceptable (Note:&#xD;
             combination medications, e.g., Combigan, are counted as two IOP-lowering medications);&#xD;
&#xD;
          7. Media clarity and pupillary dilation sufficient to allow OCT testing and assessment of&#xD;
             the fundus.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patient level exclusion criteria&#xD;
&#xD;
          1. History of infectious uveitis in either eye;&#xD;
&#xD;
          2. History of infectious scleritis of any type in either eye (Note: History of&#xD;
             noninfectious scleritis that has been active in past 12 months is an eye-level&#xD;
             exclusion -see #13 below);&#xD;
&#xD;
          3. History of keratitis (with the exception of keratitis due to dry eye) in either eye;&#xD;
&#xD;
          4. History of central serous retinopathy in either eye;&#xD;
&#xD;
          5. Active infectious conjunctivitis in either eye;&#xD;
&#xD;
          6. Oral prednisone dose &gt; 10 mg per day (or of an alternative corticosteroid at a dose&#xD;
             higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ≤ 10&#xD;
             mg per day at baseline that has not been stable for at least 4 weeks (note: if patient&#xD;
             is off of oral prednisone at baseline (M01 study visit) dose stability requirement for&#xD;
             past 4 weeks does not apply);&#xD;
&#xD;
          7. Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks&#xD;
             (note: use of systemic methotrexate is acceptable as long as regimen has been stable&#xD;
             for at least 4 weeks);&#xD;
&#xD;
          8. Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;&#xD;
&#xD;
          9. Known allergy or hypersensitivity to any component of the study drugs;&#xD;
&#xD;
         10. For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy&#xD;
             test; unwilling to practice an adequate birth control method (abstinence, combination&#xD;
             barrier and spermicide, or hormonal) for duration of trial;&#xD;
&#xD;
             Eye level exclusion criteria - at least one eye that meets all inclusion criteria&#xD;
             cannot have any of the following conditions&#xD;
&#xD;
         11. History of infectious endophthalmitis;&#xD;
&#xD;
         12. History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of ≥ 0.9&#xD;
             or any notching of optic nerve to the rim);&#xD;
&#xD;
         13. History of active noninfectious scleritis in past 12 months (Note: History of&#xD;
             noninfectious scleritis is acceptable if the last episode of active scleritis resolved&#xD;
             at least 12 months prior to enrollment);&#xD;
&#xD;
         14. Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of&#xD;
             study ophthalmologist may be significant enough to limit improvement of ME (i.e.,&#xD;
             causing substantial wrinkling of the retinal surface);&#xD;
&#xD;
         15. Torn or ruptured posterior lens capsule&#xD;
&#xD;
         16. Presence of silicone oil;&#xD;
&#xD;
         17. Ozurdex administered in past 12 weeks;&#xD;
&#xD;
         18. Anti-VEGF agent, intravitreal methotrexate, or intravitreal/periocular corticosteroid&#xD;
             administered in past 4 weeks;&#xD;
&#xD;
         19. Fluocinolone acetonide implant (Retisert) placed in past 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas A Jabs, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Clinical Trials and Evidence Synthesis, JHU, Baltimore, MD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet T Holbrook, PhD, MPH</last_name>
    <phone>443-287-5791</phone>
    <email>jholbro1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth A Sugar, PhD</last_name>
    <email>esugar2@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jules Stein Eye Institute, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Cherian</last_name>
      <phone>310-794-5604</phone>
      <email>NCherian@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Dudum</last_name>
      <phone>415-476-6687</phone>
      <email>Kathryn.Dudum@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Nisha Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Huerta</last_name>
      <phone>305-326-6348</phone>
      <email>c.huerta1@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Janet Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alcides Fernandes, MD</last_name>
      <phone>404-778-2421</phone>
      <email>afilho@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Ghazala O'Keefe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chisomo Mwale</last_name>
      <phone>312-695-2567</phone>
      <email>chisomo.mwale@nm.org</email>
    </contact>
    <investigator>
      <last_name>Anjum Koreishi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preminder (Daisy) Pacelli</last_name>
      <phone>312-563-5537</phone>
      <email>preminder_pacelli@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Pauline T Merrill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacy Flanagan, BA</last_name>
      <phone>319-467-5184</phone>
      <email>lacy-flanagan@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>B</last_name>
    </contact_backup>
    <investigator>
      <last_name>James Folk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Bottorff, BS COA CCRC</last_name>
      <phone>502-852-5251</phone>
      <email>mlbott03@exchange.louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Harpal S Sandhu, MD FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Sun</last_name>
      <phone>410-502-1873</phone>
      <email>ksun11@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Thorne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Caccaviello</last_name>
      <phone>617-573-5558</phone>
      <email>John_Caccaviello@MEEI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>George Papaliodis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredyth Parsons</last_name>
      <phone>617-314-2703</phone>
      <email>mparsons@eyeboston.com</email>
    </contact>
    <investigator>
      <last_name>Lana M Rifkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Campbell</last_name>
      <phone>734-936-0138</phone>
      <email>pamtitus@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Susan G Elner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center, Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Giron</last_name>
      <phone>215-662-9393</phone>
      <email>Alexis.Giron@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Nirali Bhatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidAtlanitc Retina, Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Kenney</last_name>
      <phone>215-928-3092</phone>
      <email>bkenney@midatlanticretina.com</email>
    </contact>
    <investigator>
      <last_name>James P Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda J Dahlstrom, MA</last_name>
      <phone>412-383-9028</phone>
      <email>dahlstromrj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Marie-Helene Errera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saige Wilkens</last_name>
      <phone>615-936-1474</phone>
      <email>saige.wilkins@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Sapna Gangaputra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsey Moore</last_name>
      <phone>713-524-3434</phone>
      <email>chelsey.moore@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Rosa Y Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John A. Moran Eye Center, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberley Wegner, BS, CRC</last_name>
      <phone>801-581-6265</phone>
      <email>kimberley.wegner@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Vitale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victorian Eye and Ear Hospital</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thuy Chau</last_name>
      <phone>+61 3 9929 8087</phone>
      <email>thuy.chau@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Lyndell Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3S5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Delpech</last_name>
      <phone>(514)934-1934</phone>
      <phone_ext>36814</phone_ext>
      <email>isabelle.delpech@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Jean Deschenes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LV Prasad Eye Institute - Bhubaneswar</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bikash Kumar</last_name>
      <email>bikash.trial@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Soumyava Basu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical and Vision Research Foundation</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salini Srikumar</last_name>
      <email>salini@snmail.org</email>
    </contact>
    <investigator>
      <last_name>Sudha Ganesh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LV Prasad Eye Institute - Hyderabad</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramya Sidagam</last_name>
      <email>sramya@lvpei.org</email>
    </contact>
    <investigator>
      <last_name>Mudit Tyagi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Eye Center, Post Graduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neetu Monga</last_name>
      <email>neetu79.monga@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yogesh Bajaj</last_name>
      <phone>0911722756111</phone>
      <email>yogeshbajaj1997@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vishali Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Paget</last_name>
      <phone>0117 342 4770</phone>
      <email>Frances.Paget@uhbristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adam Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Turnbull</last_name>
      <phone>01223 586526</phone>
      <email>paula.turnbull@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Erika Damato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Betteridge</last_name>
      <email>Carol.Betteridge@uhl-tr.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Rybicki</last_name>
      <email>lauren.rybicki@uhl-tr.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Periyasamy Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darina Koneva</last_name>
      <email>darina.koneva@rlbuht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Susan Pollard</last_name>
      <email>susan.pollard@rlbuht.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Beare, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Taylor</last_name>
      <phone>020 7253 3411</phone>
      <phone_ext>4793</phone_ext>
      <email>lauren.taylor51@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Will Tucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 (WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pippa Doyle</last_name>
      <email>Philippa.Doyle@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Romi Chhabra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B152WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire L Arthur</last_name>
      <phone>+441213718757</phone>
      <email>claire.arthur@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Alastair Denniston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 9EL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>India</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitic macular edema</keyword>
  <keyword>uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

